---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-257376"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2026-06-04T20:05:17+00:00"
generated_at: "2026-06-04T20:06:12.084937+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Fulcrum cuts workforce 85% after SCD drug failure; hires Leerink for strategic review

## Summary
- Workforce reduced from 57 to 9 employees (~85% cut) after discontinuing pociredir for sickle cell disease.
- Expects ~$4.2M in restructuring charges (severance, benefits) mostly in Q2 2026.
- Engaged Leerink Partners as financial advisor to explore strategic alternatives including merger or sale.
- No timeline set for strategic review; no assurance of any transaction.

## SEC filing metadata
- accession: 0001193125-26-257376
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2026-06-04T20:05:17+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.05, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000119312526257376/0001193125-26-257376-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000119312526257376/fulc-20260531.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-257376
- JSON: https://secwatch.observer/filing/0001193125-26-257376.json
- Plain text: https://secwatch.observer/filing/0001193125-26-257376.txt

## Key facts
- Restructurings & Charges
  Fulcrum Therapeutics, Inc. announced a restructuring with charges of approximately $4.2 million (approximately 85%, from 57 full-time employees to 9 full-time employees).
  - Type: restructuring
  - Charge: approximately $4.2 million
  - Headcount: approximately 85%, from 57 full-time employees to 9 full-time employees
  source text: On May 31, 2026, the board of directors of Fulcrum Therapeutics, Inc., or Fulcrum, approved a restructuring plan to significantly reduce Fulcrum’s operating expenses and preserve capital following the discontinuation of development of pociredir for the treatment of sickle cell disease, or SCD. The restructuring plan will reduce Fulcrum’s workforce by approximately 85%, from 57 full-time employees to 9 full-time employees, and is expected to be substantially completed during the second quarter of 2026. Fulcrum expects to incur aggregate charges of approximately $4.2 million in connection with the restructuring plan, consisting primarily of employee severance, employee benefits and related costs.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000119312526257376/0001193125-26-257376-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.